A detailed history of Citigroup Inc transactions in Novo Cure LTD stock. As of the latest transaction made, Citigroup Inc holds 82,608 shares of NVCR stock, worth $2.56 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
82,608
Previous 123,837 33.29%
Holding current value
$2.56 Million
Previous $2.12 Million 39.13%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$15.61 - $23.34 $643,584 - $962,284
-41,229 Reduced 33.29%
82,608 $1.29 Million
Q2 2024

Aug 12, 2024

BUY
$11.83 - $24.05 $150,489 - $305,940
12,721 Added 11.45%
123,837 $2.12 Million
Q1 2024

May 10, 2024

SELL
$12.42 - $17.29 $1.65 Million - $2.29 Million
-132,519 Reduced 54.39%
111,116 $1.74 Million
Q4 2023

Feb 09, 2024

BUY
$11.13 - $15.78 $2.23 Million - $3.16 Million
200,363 Added 463.03%
243,635 $3.64 Million
Q3 2023

Nov 09, 2023

SELL
$16.15 - $42.35 $703,542 - $1.84 Million
-43,563 Reduced 50.17%
43,272 $698,000
Q2 2023

Aug 10, 2023

SELL
$40.29 - $82.51 $483,480 - $990,120
-12,000 Reduced 12.14%
86,835 $3.6 Million
Q1 2023

May 11, 2023

SELL
$56.44 - $118.81 $235,185 - $495,081
-4,167 Reduced 4.05%
98,835 $5.94 Million
Q4 2022

Feb 09, 2023

BUY
$63.98 - $85.37 $1.08 Million - $1.44 Million
16,905 Added 19.63%
103,002 $7.56 Million
Q3 2022

Nov 10, 2022

BUY
$67.99 - $89.57 $357,559 - $471,048
5,259 Added 6.51%
86,097 $6.54 Million
Q2 2022

Aug 10, 2022

SELL
$56.6 - $89.9 $74,485 - $118,308
-1,316 Reduced 1.6%
80,838 $5.62 Million
Q1 2022

May 12, 2022

SELL
$60.15 - $84.52 $3.99 Million - $5.61 Million
-66,411 Reduced 44.7%
82,154 $6.81 Million
Q4 2021

Feb 10, 2022

BUY
$75.08 - $121.99 $2.69 Million - $4.37 Million
35,806 Added 31.75%
148,565 $11.2 Million
Q3 2021

Nov 10, 2021

BUY
$116.17 - $194.55 $13.1 Million - $21.9 Million
112,759 New
112,759 $13.1 Million

Others Institutions Holding NVCR

About NovoCure Ltd


  • Ticker NVCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 104,950,000
  • Market Cap $3.25B
  • Description
  • NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...
More about NVCR
Track This Portfolio

Track Citigroup Inc Portfolio

Follow Citigroup Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citigroup Inc, based on Form 13F filings with the SEC.

News

Stay updated on Citigroup Inc with notifications on news.